Article thumbnail

β1 integrin mediates an alternative survival pathway in breast cancer cells resistant to lapatinib

By Catherine Huang, Catherine C Park, Susan G Hilsenbeck, Robin Ward, Mothaffar F Rimawi, Yen-chao Wang, Jiang Shou, Mina J Bissell, C Kent Osborne and Rachel Schiff
Topics: Research Article
Publisher: BioMed Central
OAI identifier: oai:pubmedcentral.nih.gov:3236347
Provided by: PubMed Central

Suggested articles

Citations

  1. (2009). Abdulkarim B: {beta}1-integrin circumvents the antiproliferative effects of trastuzumab in human epidermal growth factor receptor-2-positive breast cancer. Cancer Res
  2. (2004). AV: Regulatory nodes that integrate and coordinate signaling as potential targets for breast cancer therapy. Clin Cancer Res
  3. (2001). Biology of HER2 and its importance in breast cancer. Oncology
  4. CC: Breast cancer cells in threedimensional culture display an enhanced radioresponse after coordinate targeting of integrin alpha5beta1 and fibronectin.
  5. (2007). CL: Human breast cancer cells selected for resistance to trastuzumab in vivo overexpress epidermal growth factor receptor and ErbB ligands and remain dependent on the ErbB receptor network. Clin Cancer Res
  6. (2009). Different mechanisms for required resistance to trastuzumab and lapatinib in HER2 positive breast cancers: role of ER and HER2 reactivation. San Antonio Breast Cancer Symposium
  7. (2006). Elledge RM: EGFR expression in breast cancer: association with biologic phenotype, prognosis, and resistance to adjuvant therapy.
  8. (2007). Esteva FJ: Lapatinib induces apoptosis in trastuzumab-resistant breast cancer cells: effects on insulin-like growth factor I signaling. Mol Cancer Ther
  9. (2007). Esteva FJ: Trastuzumab: triumphs and tribulations. Oncogene
  10. (2007). Extracellular matrix regulation of drug resistance in small-cell lung cancer.
  11. (2007). GG: HER-2-positive breast cancer: hope beyond trastuzumab. BioDrugs
  12. (2006). Giancotti FG: Beta 4 integrin amplifies ErbB2 signaling to promote mammary tumorigenesis. Cell
  13. (2010). Hortobagyi GN: Molecular predictors of response to trastuzumab and lapatinib in breast cancer. Nat Rev Clin Oncol
  14. (1999). Integrin function in breast carcinoma progression.
  15. (2007). JT: Cellular characterization of a novel focal adhesion kinase inhibitor.
  16. (2006). JW: A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes. Cancer Cell
  17. (2009). KL: Understanding the mechanisms behind trastuzumab therapy for human epidermal growth factor receptor 2-positive breast cancer.
  18. (2009). Lapatinib, a HER2 tyrosine kinase inhibitor, induces stabilization and accumulation of HER2 and potentiates trastuzumab-dependent cell cytotoxicity. Oncogene
  19. (2008). Met receptor contributes to trastuzumab resistance of Her2-overexpressing breast cancer cells. Cancer Res
  20. (2008). MJ: Beta1 integrin inhibition dramatically enhances radiotherapy efficacy in human breast cancer xenografts. Cancer Res
  21. (2006). MJ: Beta1 integrin inhibitory antibody induces apoptosis of breast cancer cells, inhibits growth, and distinguishes malignant from normal phenotype in three dimensional cultures and in vivo. Cancer Res
  22. (2010). MJ: HER2 signaling pathway activation and response of breast cancer cells to HER2-targeting agents is dependent strongly on the 3D microenvironment. Breast Cancer Res Treat
  23. (1998). MJ: Reciprocal interactions between beta1-integrin and epidermal growth factor receptor in three-dimensional basement membrane breast cultures: a different perspective in epithelial biology.
  24. (2007). MJ: The morphologies of breast cancer cell lines in three-dimensional assays correlate with their profiles of gene expression. Mol Oncol
  25. (2006). NL: A model of acquired autoresistance to a potent ErbB2 tyrosine kinase inhibitor and a therapeutic strategy to prevent its onset in breast cancer. Proc Natl Acad Sci USA
  26. (2009). O’Donovan N: HER-2 signaling and inhibition in breast cancer. Curr Cancer Drug Targets
  27. (2009). Ormandy CJ: Meta-analysis and gene set enrichment relative to ER status reveal elevated activity of MYC and E2F in the “basal” breast cancer subgroup. PLoS One
  28. (2007). Park CC: beta1 integrin as a molecular therapeutic target.
  29. (2008). Perou CM: The functional loss of the retinoblastoma tumour suppressor is a common event in basal-like and luminal B breast carcinomas. Breast Cancer Res
  30. (1997). Reversion of the malignant phenotype of human breast cells in three-dimensional culture and in vivo by integrin blocking antibodies.
  31. (2006). RI: Elevated Src activity promotes cellular invasion and motility in tamoxifen resistant breast cancer cells. Breast Cancer Res Treat
  32. (2006). Role of c-Src and focal adhesion kinase in progression and metastasis of estrogen receptor-positive breast cancer. Biochem Biophys Res Commun
  33. (1999). Ruoslahti E: Integrin signaling. Science
  34. (2006). Schlaepfer DD: Integrin-regulated FAK-Src signaling in normal and cancer cells. Curr Opin Cell Biol
  35. (2006). Slamon DJ: Activity of the dual kinase inhibitor lapatinib (GW572016) against HER-2-overexpressing and trastuzumab-treated breast cancer cells. Cancer Res
  36. (2009). Src and FAK mediate cell-matrix adhesiondependent activation of Met during transformation of breast epithelial cells.
  37. (2008). T: Frequent PTEN genomic alterations and activated phosphatidylinositol 3-kinase pathway in basal-like breast cancer cells. Breast Cancer Res
  38. (2001). Tani T: Integrin laminin receptors and breast carcinoma progression.
  39. (2009). TM: Novel mechanism of lapatinib resistance in HER2-positive breast tumor cells: activation of AXL. Cancer Res
  40. (2007). Trastuzumab-mechanism of action and use in clinical practice.
  41. (2007). Trastuzumab: mechanism of action, resistance and future perspectives in HER2-overexpressing breast cancer. Ann Oncol
  42. (2007). Treatment of human epidermal growth factor receptor 2-overexpressing breast cancer xenografts with multiagent HER-targeted therapy.
  43. (2009). Updated survival analysis of a randomized study of lapatinib alone or in combination with trastuzumab in women with HER2-positive metastatic breast cancer progressing on trastuzumab therapy. Cancer Res
  44. (2001). VM: Tumour-stromal interactions. Integrins and cell adhesions as modulators of mammary cell survival and transformation. Breast Cancer Res
  45. (2001). Vuori K: Integrin signaling inhibits paclitaxel-induced apoptosis in breast cancer cells. Oncogene
  46. (1999). WS: Cell adhesion mediated drug resistance (CAM-DR): role of integrins and resistance to apoptosis in human myeloma cell lines. Blood
  47. (2006). Yarden Y: EGF-ERBB signalling: towards the systems level. Nat Rev Mol Cell Biol

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.